Total Clarity Wealth Management’s NovoCure NVCR Stock Holding History

Total Clarity Wealth Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-140	Closed	-$10K	–	726
2022 Q2	$10K	Buy	+140	New	+$10.5K	0.01%	671
2022 Q1	–	Sell	-20	Closed	-$2K	–	669
2021 Q4	$2K	Sell	20 -6,625	-100%	-$665K	﹤0.01%	920
2021 Q3	$772K	Buy	6,645 +1,585	+31%	+$240K	0.37%	70
2021 Q2	$1.12M	Sell	5,060 -75	-1%	-$14.6K	0.63%	48
2021 Q1	$679K	Sell	5,135 -5,135	-50%	-$812K	0.39%	63
2020 Q4	$1.78M	Sell	10,270 -150	-1%	-$20.5K	1.23%	22
2020 Q3	$1.16M	Buy	10,420 +250	+2%	+$20K	1.01%	28
2020 Q2	$603K	Buy	+10,170	New	+$669K	0.55%	51
2020 Q1	–	Sell	-60	Closed	-$5K	–	447
2019 Q4	$5K	Buy	+60	New	+$4.84K	﹤0.01%	587

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Total Clarity Wealth Management's NVCR Position: Q3 2022 in Review

Total Clarity Wealth Management sold out of NovoCure (NVCR) in Q3 2022, closing a stake of 140 shares — an estimated $10K sold.

Total Clarity Wealth Management first reported a position in NVCR in Q4 2019 and held it in 9 quarters. The position peaked at $1.78M in Q4 2020. 303 funds tracked by Wall St. Rank hold NVCR as of Q3 2022.

Total Clarity Wealth Management reported no remaining NovoCure position as of Q3 2022 after selling out during the quarter.
Total Clarity Wealth Management sold 140 NovoCure shares in Q3 2022, an estimated $10K.
Total Clarity Wealth Management first reported a position in NovoCure in Q4 2019 and held it in 9 quarters.
Total Clarity Wealth Management's NovoCure position peaked at $1.78M in Q4 2020.
303 funds tracked by Wall St. Rank held NovoCure as of Q3 2022.

Based on Total Clarity Wealth Management's 13F filing for Q3 2022, filed 4 Nov 2022.